KEY-T 0.18 BIP.UN-T -0.15 POW-T -0.1 BBD.B-T 1.53 UNH-N -5.61 NTR-T 0.52 TGT-N 1.27
Daily Stock Opinions and Ratings
The ultimate 360° Tracker Your financial life in one place, automatically
Stockchase Opinions

Jim Cramer - Mad Money Dexcom DXCM-Q DON'T BUY Aug 07, 2024

Their quarter missed badly and they haven't fully explained why.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$70.470

Stock price when the opinion was issued

0
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

HOLD

Dexcom(DXCM-Q)

Oct 15, 2020
Medical devices. Monitor diabetes. Recurring revenue from disposable sensors. M&A potential. Really likes the sector. Stick with it.
James TelfserJames Telfser
No
Unlock Rating
$396.750

Stock price when the opinion was issued

0
COMMENT

Dexcom(DXCM-Q)

Dec 09, 2020
The stock got overheated and has pulled back. It's up over 50% YTD. The quarter they reported in late-October was imperfect with a big earnings beat but a smaller sales beat compared to previous quarter. Their new blood sugar monitor is rolling out in only some key markets in 2021, not in all key ones until 2023. Both factors led to the stock getting hurt. Today, management guided for 15-20% growth through 2025, but fell short of expectations. The stock sold off today.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$333.390

Stock price when the opinion was issued

0
BUY

Dexcom(DXCM-Q)

Feb 12, 2021
They make blood-sugar monitor for diabetics. He has long liked this. Performed well last year until Covid delayed the development in their new device which happened when the market lost interest in health stocks. But a few months ago, it started to come back. Yesterday, they reported a mixed quarter with a nice revenue beat, but small earnings miss, yet offered conservative guidance expand overseas. It fell 5% today. Likes that they're spending money to grow and their conservative nature.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$412.560

Stock price when the opinion was issued

0
COMMENT

Dexcom(DXCM-Q)

Jan 10, 2022
They make blood sugar monitors used by diabetics. One of the best growth stocks of the last 5 years, from $60 from end-2017 to $659 last November. Since then, it's plunged to $462. Today, the company reported Q4 sales were in line and issued cautious guidance for 2022. They under-promise and over-delivered.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$462.340

Stock price when the opinion was issued

0
COMMENT

Dexcom(DXCM-Q)

Oct 19, 2022
Shares are expensive, but their diabetes machine is the best. Likes it, but these expensive stocks have had a hard time in this market.
Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$96.840

Stock price when the opinion was issued

0
DON'T BUY

Dexcom(DXCM-Q)

Jun 05, 2023
The Saudi/OPEC oil cut today

He regrets he didn't sell some of his oil holdings today. He doesn't see the price of oil moving up from here, but will move down.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$124.700

Stock price when the opinion was issued

0
DON'T BUY

Dexcom(DXCM-Q)

Sep 15, 2023

Does well when (sadly) diabetes is booming. The fear is that drugs develop from Novo Nordisk and Eli Lilly will cut down on diabetes. He tends to agree. Be careful here.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$97.050

Stock price when the opinion was issued

0
BUY ON WEAKNESS

Dexcom(DXCM-Q)

Oct 11, 2023
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

DXCM has been hit hard as investors fear new success of weight loss drugs will reduce demand for diabetes monitoring products. DXCM is not alone in the decline. But it is still growing, and recent comments by analysts suggest the sell off is quite overdone. It has new products on tap and is strong financially. Market share remains robust. Best Buy has started selling its products (not material on its own, but shows an expanding footprint). We would see DXCM as worth holding. Because it is 33X as large was WELL, they are hard to compare. WELL, being smaller, could potentially rise more, but comes with much more overall risk. From a safety and valuation standpoint, we would, today, prefer DXCM.
Unlock Premium - Try 5i Free

Stockchase InsightsStockchase Insights
Unknown
Unlock Rating
$78.040

Stock price when the opinion was issued

0
DON'T BUY

Dexcom(DXCM-Q)

Oct 21, 2024

Their last quarter was very bad. He lost faith.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$72.610

Stock price when the opinion was issued

0

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

CLS-T -3.91$123.45
NVDA-Q 4.58$111.01
PEP-Q -1.93$133.38
IBM-N 3.08$232.41
RMD-N -0.22$235.88

Today's Top Picks

KEY-T 0.18$42.62
BIP.UN… -0.15$39.97
POW-T -0.1$50.8
BBD.B-… 1.53$91.21
UNH-N -5.61$418.64

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

ARE-T -0.27$15.4
CVX-N -0.34$138.73
XOM-N -0.06$108.57
CNQ-T -0.01$40.68
TD-T -0.03$86.17

Most Recent Experts

Greg Newman

Scotia Wealth Management

Stockchase Insights

5i Research

Jim Cramer - Mad Money

CNBC

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

© Stockchase Inc.